Literature DB >> 15273582

Personal digital assistants used to document compliance of bacterial vaginosis treatment.

Jennifer B Bartley1, Daron G Ferris, Lynn M Allmond, Eileen D Dickman, James K Dias, Jerry Lambert.   

Abstract

OBJECTIVE: The objective of this study was to estimate patient compliance with oral and vaginal metronidazole treatment of bacterial vaginosis using personal digital assistants (PDAs) and paper diaries. GOAL: The goal of this study was to assess a novel compliance documentation approach. STUDY: After each dose of intravaginal or oral metronidazole, 71 subjects recorded the time on a paper diary and answered questions on a PDA. All PDA entries were unknowingly time-date-stamped. Subjects returned for 2- and 6-week posttreatment examinations. Compliance was calculated using a repeated-measures multivariate analysis of variance (ANOVA).
RESULTS: Mean patient compliance rates within the oral metronidazole group were greater with the paper diary compared with the PDA (68.3% and 50.0%, respectively, P = 0.001). The observed rate of compliance agreement for PDA versus paper diary was 69.0% (kappa = 0.4). The majority of noncompliant subjects reported they were compliant with the PDA and paper diary.
CONCLUSIONS: PDAs could more accurately document true compliance rates and could be reasonable instruments to assess compliance in intravaginal antimicrobial drug or contraceptive trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273582     DOI: 10.1097/01.olq.0000135990.21755.51

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  6 in total

1.  The feasibility of cell phone based electronic diaries for STI/HIV research.

Authors:  Devon J Hensel; James D Fortenberry; Jaroslaw Harezlak; Dorothy Craig
Journal:  BMC Med Res Methodol       Date:  2012-06-12       Impact factor: 4.615

2.  Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.

Authors:  Helen S Pentikis; Nikki Adetoro
Journal:  Clin Pharmacol Drug Dev       Date:  2017-11-10

3.  Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jane R Schwebke; Shelly Y Lensing; Jeannette Lee; Christina A Muzny; Angela Pontius; Nicole Woznicki; Tina Aguin; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

4.  Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals.

Authors:  Borje Darpo; Hongqi Xue; Nikki Adetoro; Barbara G Matthews; Helen S Pentikis
Journal:  J Clin Pharmacol       Date:  2017-10-02       Impact factor: 3.126

5.  Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.

Authors:  Christina A Muzny; Jane R Schwebke; Paul Nyirjesy; Gregory Kaufman; Leandro A Mena; Gweneth B Lazenby; Olivia T Van Gerwen; Keonte J Graves; Janeen Arbuckle; Belvia A Carter; Connette P McMahon; Scott Eder; Jackie Shaw; Brajesh Pandey; Steven E Chavoustie
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

Review 6.  A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis.

Authors:  Christina A Muzny; Przemyslaw Kardas
Journal:  Sex Transm Dis       Date:  2020-07       Impact factor: 3.868

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.